PTCT Q4 2023 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$307M+83.4% YoY

Gross Profit

$201M65.4% margin

Operating Income

$3M1.0% margin

Net Income

-$156M-50.7% margin

EPS (Diluted)

$-2.06

QoQ Revenue Growth

+56.2%

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$129M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$2.7B

Stockholders' Equity

-$819M

Cash & Equivalents

$594M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$307M	$167M	+83.4%
Gross Profit	$201M	$157M	+28.3%
Operating Income	$3M	-$200M	+101.6%
Net Income	-$156M	-$171M	+8.8%

Revenue Segments

Manufacturing

$3M100%

Geographic Segments

United States

$344M74%

Non-US

$118M26%